← Back to headlines
Beam Therapeutics Releases 18-Month Data for AATD Gene Therapy
Beam Therapeutics has published interim clinical results for its BEAM-302 gene therapy candidate, demonstrating sustained efficacy and safety profiles over an 18-month treatment period for alpha-1 antitrypsin deficiency.
8 Sept, 10:04 — 8 Sept, 10:04
Sources
Showing 1 of 1 sources
